Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.51 | N/A | -33.16% |
management commentary, guidance changes, and full analysis available with Pro.
| -33.16% |
Tone: Defensive
Management expressed concerns about the current business environment. They emphasized their commitment to addressing challenges and maintaining stakeholder value.
We are focused on navigating the current challenges in our business.
Our priorities remain on delivering value to our stakeholders.
Neurocrine Biosciences reported a larger-than-expected loss in EPS, which contributed to a 5.7% drop in stock price. The lack of revenue information and no forward guidance may have added to investor uncertainty. Overall, the company appears to be facing challenges that could affect its performance in the near term.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PORTLAND GEN ELEC CO